Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101

Inclusion Criteria: * Patients with advanced or recurrent or metastatic gastrointestinal adenocarcinoma. * Premature or scheduled termination of standard therapy * Progressive disease as clinically assessed by the investigator * Max. tumour lesion ≤ 5 cm * Adequate organ function * Ability of patient to understand character and individual consequences of clinical trial * Age ≥ 18 years * Written informed consent must be available before any study specific procedure is performed Exclusion Criteria: * Patients with severe heart diseases * Clinical significant ischemic disease during the last 4 weeks before Visit 1 * Severe lung disease * Symptomatic peritoneal carcinomatosis * Symptomatic pleural or pericardial effusion * Serious uncontrolled acute infections less than 3 weeks before Visit 1 * Known dependency on alcohol or other drugs * Patients requiring corticoids in doses above the Cushing threshold * Known liver fibrosis or liver cirrhosis * Any concomitant severe disease which could compromise the objectives of this study in the judgment of the investigator * Female patient who is pregnant or breast feeding * Participation in another clinical trial or observation period, respectively, during the last 4 weeks prior to the first IMP dose